Four big startup fundraising rounds and one major acquisition in the biotech space make up the finalists in this year’s Deal of the Year category at the 2024 GeekWire Awards.… Read More
Biotech giant AstraZeneca has completed its $1.1 billion acquisition of Icosavax, a Seattle-based spinout from the University of Washington’s Institute for Protein Design.
Seattle-based Icosavax, a spin-out from the University of Washington’s Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.1 billion. The pending acquisition, announced Tuesday, values… Read More
Seattle-based vaccine company Icosavax posted disappointing clinical data today for its experimental COVID-19 vaccine, sending its stock into a dive. Icosavax went public last June in an IPO that raised… Read More
— Leafly announced its new six-member board of directors whose appointments will be effective after its pending SPAC merger with New York-based Merida Merger Corp is completed. The new board… Read More
— The Allen Institute for AI (AI2) added bioengineer Jenny Cronin as a principal working with entrepreneurs in AI2’s startup incubator. “I’m excited about the potential human health benefits and… Read More
— Amy Nelson is getting back into co-working. The founder and former CEO of The Riveter announced Tuesday that she is the president of SaksWorks, a new partnership between Saks… Read More
Icosavax is having quite the debut as Washington state’s newest public company. Shares of the Seattle-based biotech firm surged more than 200% on its first day of trading Thursday. Icosavax… Read More
An experimental COVID-19 vaccine in development by Seattle-based HDT Bio will enter early-stage clinical trials in the U.S., the company announced yesterday after the U.S. Food and Drug Administration cleared… Read More
A project to test what’s being called an ultrapotent, second-generation COVID-19 vaccine candidate will receive up to $173.4 million to conduct phase 3 clinical trials. The vaccine was developed in… Read More
Innovators across the Seattle area are tackling problems big and small with a variety of breakthroughs and technologies. Whether it’s improved battery performance, better vaccines, an easier way to purchase… Read More
New funding: At a moment when vaccines are on everyone’s mind, a Seattle-based biotech company that has an unusual approach to vaccine production has raised $100 million in a Series… Read More
Seattle-based biotech startup Icosavax today scored $51 million in funding to create vaccines from artificial viruses. The Series A financing was led by Qiming Venture Partners USA along with Adams… Read More